{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:44:07Z","timestamp":1792212247944,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.euf.2018.04.005","type":"journal-article","created":{"date-parts":[[2018,4,14]],"date-time":"2018-04-14T08:01:48Z","timestamp":1523692908000},"page":"17-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Lower Urinary Tract Symptoms: What\u2019s New in Medical Treatment?"],"prefix":"10.1016","volume":"4","author":[{"given":"Benoit","family":"Peyronnet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4161-8467","authenticated-orcid":false,"given":"Martin C.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2018.04.005_bib0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ucl.2016.04.013","article-title":"\u03b1-Blockers, 5-\u03b1-reductase inhibitors, acetylcholine, \u03b23 agonists, and phosphodiesterase-5s in medical management of lower urinary tract symptoms\/benign prostatic hyperplasia: how much do the different formulations actually matter in the classes?","volume":"43","author":"Chughtai","year":"2016","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.euf.2018.04.005_bib0010","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/ijcp.12433","article-title":"Safety and tolerability of the \u03b23-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised phase III trials and of a 1-year randomised phase III trial","volume":"68","author":"Nitti","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.euf.2018.04.005_bib0015","doi-asserted-by":"crossref","unstructured":"Gibson W, MacDiarmid S, Huang M, et al. Treating overactive bladder in older patients with a combination of mirabegron and solifenacin: a prespecified analysis from the BESIDE study. Eur Urol Focus [In press]. https:\/\/doi.org\/10.1016\/j.euf.2017.08.008.","DOI":"10.1016\/j.euf.2017.08.008"},{"key":"10.1016\/j.euf.2018.04.005_bib0020","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.juro.2014.09.091","article-title":"A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction","volume":"193","author":"Ichihara","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.04.005_bib0025","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1517\/14740338.2016.1160055","article-title":"Safety and tolerability of \u03b23-adrenoceptor agonists in the treatment of overactive bladder syndrome\u2014insight from transcriptosome and experimental studies","volume":"15","author":"Michel","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.euf.2018.04.005_bib0030","unstructured":"Medicines and Healthcare Regulatory Agency; 2015. https:\/\/www.gov.uk\/drug-safety-update\/mirabegron-betmiga-risk-of-severe-hypertension-and-associated-cerebrovascular-and-cardiac-events."},{"key":"10.1016\/j.euf.2018.04.005_bib0035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1476-5381.2010.01005.x","article-title":"Are there functional \u03b23-adrenoceptors in the human heart?","volume":"162","author":"Michel","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.euf.2018.04.005_bib0040","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/bph.13897","article-title":"The \u03b23-adrenoceptor agonist mirabegron increases human atrial force through \u03b21-adrenoceptors: an indirect mechanism?","volume":"174","author":"Mo","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.euf.2018.04.005_bib0045","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pharmthera.2016.01.007","article-title":"\u03b23-Adrenoceptor agonists for overactive bladder syndrome: role of translational pharmacology in a repositioning clinical drug development project","volume":"159","author":"Michel","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.euf.2018.04.005_bib0050","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2012.05.053","article-title":"A multicenter, double-blind, randomized, placebo-controlled trial of the \u03b23-adrenoceptor agonist solabegron for overactive bladder","volume":"62","author":"Ohlstein","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.04.005_bib0055","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cpdd.212","article-title":"Investigation of drug-drug interactions between ritobegron, a selective \u03b23-adrenoceptor agonist, with probenecid in healthy men","volume":"5","author":"Abe","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.euf.2018.04.005_bib0060","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1021\/acs.jmedchem.5b01372","article-title":"Discovery of vibegron: a potent and selective \u03b23 adrenergic receptor agonist for the treatment of overactive bladder","volume":"59","author":"Edmondson","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.euf.2018.04.005_bib0065","doi-asserted-by":"crossref","unstructured":"Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Vibegron, a novel potent and selective \u03b23-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol [In press]. https:\/\/doi.org\/10.1016\/j.eururo.2017.12.022.","DOI":"10.1016\/j.eururo.2017.12.022"},{"key":"10.1016\/j.euf.2018.04.005_bib0070","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2015.12.048","article-title":"Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"70","author":"Gacci","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.04.005_bib0075","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1464-410X.2010.09205.x","article-title":"A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder","volume":"106","author":"Giuliano","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.04.005_bib0080","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.urology.2016.11.008","article-title":"Efficacy of daily low-dose tadalafil for treating overactive bladder: results of a randomized, double-blind, placebo-controlled trial","volume":"100","author":"Chen","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.euf.2018.04.005_bib0085","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s11255-017-1671-2","article-title":"Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast","volume":"49","author":"Ding","year":"2017","journal-title":"Int Urol Nephrol"},{"issue":"3 Suppl 1","key":"10.1016\/j.euf.2018.04.005_bib0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.urology.2003.10.005","article-title":"New pharmacologic targets for the treatment of the overactive bladder: an update","volume":"63","author":"Andersson","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.euf.2018.04.005_bib0095","doi-asserted-by":"crossref","unstructured":"Chua ME, See MC 4th, Esme\u0148a EB, Balingit JC, Morales ML Jr. Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment. Low Urin Tract Symptoms [in press]. https:\/\/doi.org\/10.1111\/luts.12152.","DOI":"10.1111\/luts.12152"},{"key":"10.1016\/j.euf.2018.04.005_bib0100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/nau.20928","article-title":"Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder","volume":"30","author":"Marencak","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2018.04.005_bib0105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nrurol.2016.95","article-title":"Does central sensitization help explain idiopathic overactive bladder?","volume":"13","author":"Reynolds","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2018.04.005_bib0110","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/ijcp.12409","article-title":"Clinical safety, tolerability and efficacy of combination tolterodine\/pilocarpine in patients with overactive bladder","volume":"68","author":"Dmochowski","year":"2014","journal-title":"Int J Clin Pract"},{"issue":"Suppl 3","key":"10.1016\/j.euf.2018.04.005_bib0115","first-page":"S45","article-title":"Efficacy and safety of combination of tolterodine and pilocarpine in overactive bladder patients: a randomized double-blind multicenter phase 3 study","volume":"36","author":"Lee","year":"2017","journal-title":"Neurourol Urodyn"},{"issue":"Suppl 3","key":"10.1016\/j.euf.2018.04.005_bib0120","first-page":"S26","article-title":"Chapter 5: clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB)","volume":"33","author":"Cruz","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2018.04.005_bib0125","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.juro.2014.07.008","article-title":"Bladder instillation of liposome encapsulated onabotulinumtoxinA improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial","volume":"192","author":"Chuang","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.04.005_bib0130","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2016.09.032","article-title":"Comparative effectiveness of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review and meta-analysis","volume":"71","author":"Dahm","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.04.005_bib0135","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/2040622311423128","article-title":"The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians","volume":"2","author":"Shore","year":"2011","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.euf.2018.04.005_bib0140","doi-asserted-by":"crossref","unstructured":"Shore N, Tutrone R, Efros M, et al. Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement. World J Urol [in press]. https:\/\/doi.org\/10.1007\/s00345-018-2185-y.","DOI":"10.1007\/s00345-018-2185-y"},{"key":"10.1016\/j.euf.2018.04.005_bib0145","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.juro.2014.02.004","article-title":"A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxin A 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"192","author":"McVary","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.04.005_bib0150","doi-asserted-by":"crossref","unstructured":"Totaro A, Pinto F, Pugliese D, et al. Intraprostatic botulinum toxin type A injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: a randomized, double-blind, controlled trial using urodynamic evaluation. Neurourol Urodyn [in press]. https:\/\/doi.org\/10.1002\/nau.23390.","DOI":"10.1002\/nau.23390"},{"key":"10.1016\/j.euf.2018.04.005_bib0155","doi-asserted-by":"crossref","unstructured":"Robert G, Descazeaud A, Karsenty G, et al. Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial. World J Urol [In press]. https:\/\/doi.org\/10.1007\/s00345-018-2193-y.","DOI":"10.1007\/s00345-018-2193-y"},{"key":"10.1016\/j.euf.2018.04.005_bib0160","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17512433.2017.1394185","article-title":"Desmopressin acetate nasal spray for adults with nocturia","volume":"10","author":"Cohn","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.euf.2018.04.005_bib0165","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/nau.22760","article-title":"Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis\/bladder pain syndrome refractory to conventional treatment\u2014a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial","volume":"35","author":"Kuo","year":"2016","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2018.04.005_bib0170","doi-asserted-by":"crossref","unstructured":"Pinto R, Costa D, Morgado A, et al. Intra-trigonal onabotulinum toxin A improves bladder symptoms and quality of life in bladder pain syndrome\/interstitial cystitis patients\u2014a pilot, single centre, randomized, double-blind, placebo-controlled trial. J Urol [in press]. https:\/\/doi.org\/10.1016\/j.juro.2017.10.018.","DOI":"10.1016\/j.juro.2017.10.018"},{"key":"10.1016\/j.euf.2018.04.005_bib0175","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/nau.22438","article-title":"Neurotrophins in bladder function: what do we know and where do we go from here?","volume":"33","author":"Cruz","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2018.04.005_bib0180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12894-016-0193-z","article-title":"Fulranumab in patients with interstitial cystitis\/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Urol"},{"key":"10.1016\/j.euf.2018.04.005_bib0185","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.juro.2016.03.003","article-title":"A phase II study of the efficacy and safety of the novel oral SHIP1 activator AQX-1125 in subjects with moderate to severe interstitial cystitis\/bladder pain syndrome","volume":"196","author":"Nickel","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.04.005_bib0190","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/nau.22954","article-title":"Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport\u00ae (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study","volume":"36","author":"Denys","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2018.04.005_bib0195","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/sc.2015.195","article-title":"Initial experience with the treatment of neurogenic detrusor overactivity with a new \u03b2-3 agonist (mirabegron) in patients with spinal cord injury","volume":"54","author":"W\u00f6llner","year":"2016","journal-title":"Spinal Cord"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918300944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918300944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:46:21Z","timestamp":1762497981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456918300944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S2405456918300944"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2018.04.005","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower Urinary Tract Symptoms: What\u2019s New in Medical Treatment?","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2018.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}